Actively Recruiting
Master Protocol Platform Study Evaluating Safety and Efficacy of Multiple Drug Regimens in Adults With Myasthenia Gravis
Led by argenx · Updated on 2026-10-26
70
Participants Needed
37
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of various drug regimens for people with myasthenia gravis, a condition that affects muscle strength. This platform study uses a master protocol allowing multiple treatments to be tested separately but under a common framework. The goal is to find treatments that reduce side effects and improve quality of life. Participants may receive treatments including intravenous infusions of efgartigimod, empasiprubart, or placebo, as well as subcutaneous injections of efgartigimod PH20 using a pre-filled syringe. The study includes different treatment groups based on specific myasthenia gravis subtypes and prior responses to therapy. Each treatment period varies in length depending on the specific intervention appendix. Throughout the study, participants undergo screening, treatment, and follow-up periods lasting up to approximately seven years depending on the treatment group. Researchers will monitor safety and tolerability as the primary outcomes, along with evaluating how well the treatments work. Participants will have regular assessments and safety monitoring throughout their involvement in the platform study.
CONDITIONS
Brief Title
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Research Team
S
Sabine Coppieters, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here